Granules India subsidiary receives USFDA nod for ADHD treatment drug

Granules India Share Price | The pharmaceutical company, in an exchange filing on Tuesday, said its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has been granted approval from the US health regulator for its Abbreviated New Drug Application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets.

Leave a Reply

Your email address will not be published. Required fields are marked *